NxStage Medical, Inc. (NASDAQ:NXTM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. “

A number of other equities analysts also recently issued reports on the stock. Jefferies Group LLC decreased their price target on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Canaccord Genuity downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target for the company. in a research note on Monday. BidaskClub downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Craig Hallum assumed coverage on shares of NxStage Medical in a research note on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price target for the company. Finally, Stephens downgraded shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $33.00 to $30.00 in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. NxStage Medical presently has a consensus rating of “Hold” and an average price target of $30.29.

NxStage Medical (NXTM) opened at 29.28 on Friday. The company’s market capitalization is $1.93 billion. The stock has a 50 day moving average price of $24.75 and a 200 day moving average price of $25.82. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.46%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.03) earnings per share. Equities research analysts forecast that NxStage Medical will post ($0.03) earnings per share for the current year.

WARNING: “NxStage Medical, Inc. (NASDAQ:NXTM) Downgraded by Zacks Investment Research to Hold” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/nxstage-medical-inc-nasdaqnxtm-downgraded-by-zacks-investment-research-to-hold/1471585.html.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 24,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $29.64, for a total transaction of $711,360.00. Following the completion of the transaction, the president now owns 82,903 shares of the company’s stock, valued at $2,457,244.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $29.26, for a total transaction of $29,260.00. Following the transaction, the president now directly owns 74,903 shares of the company’s stock, valued at approximately $2,191,661.78. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,900 shares of company stock valued at $1,404,073. 4.70% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in NXTM. Emory University acquired a new position in shares of NxStage Medical during the second quarter worth $1,804,000. TIAA CREF Investment Management LLC increased its position in shares of NxStage Medical by 1.0% in the second quarter. TIAA CREF Investment Management LLC now owns 215,788 shares of the medical device company’s stock worth $5,410,000 after buying an additional 2,129 shares in the last quarter. Teachers Advisors LLC increased its position in shares of NxStage Medical by 7.6% in the second quarter. Teachers Advisors LLC now owns 127,899 shares of the medical device company’s stock worth $3,206,000 after buying an additional 9,074 shares in the last quarter. Delta Lloyd Asset Management N.V. acquired a new position in shares of NxStage Medical during the second quarter worth $4,638,000. Finally, Swiss National Bank increased its position in shares of NxStage Medical by 3.4% in the second quarter. Swiss National Bank now owns 109,700 shares of the medical device company’s stock worth $2,750,000 after buying an additional 3,600 shares in the last quarter. 91.11% of the stock is owned by institutional investors and hedge funds.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.